Anaptysbio (ANAB) EBITDA Margin (2016 - 2026)
Anaptysbio (ANAB) reported EBITDA Margin of 207.41% for Q1 2026, down 6527.0% on a YoY basis from 3.23% in Q1 2025, and down 413.99% quarter-over-quarter from 66.06% in Q4 2025.
Anaptysbio (ANAB) EBITDA Margin (2016 - 2026) Analysis & Trends
Anaptysbio has reported EBITDA Margin for 11 years, with the latest figure at 207.41% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin fell 6527.0% year-over-year to 207.41%; the trailing twelve-month figure through Mar 2026 stood at 15.68% (up 16191.0% YoY), and the FY2025 full-year result was 5.78%, up 15212.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 207.41%, down from 66.06% in the prior quarter.
- The five-year high for EBITDA Margin was 66.06% in Q4 2025, with the low at 3945.05% in Q1 2022.
- Historically, EBITDA Margin has averaged 1032.14% across 5 years, with a median of 451.5% in 2023.
- The largest YoY upside for EBITDA Margin was 272732 bps in 2022 against a maximum downside of 376235 bps in 2022.
- Anaptysbio's EBITDA Margin stood at 513.04% in 2022, then rose by 12 bps to 451.5% in 2023, then jumped by 80 bps to 88.95% in 2024, then soared by 174 bps to 66.06% in 2025, then plunged by 414 bps to 207.41% in 2026.
- The last three EBITDA Margin figures came in at 207.41% (Q1 2026), 66.06% (Q4 2025), and 30.33% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Anaptysbio | 1.66 Bn | 1.38 Bn | - | -207.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -207.41% |
| Dec 31, 2025 | 66.06% |
| Sep 30, 2025 | 30.33% |
| Jun 30, 2025 | -174.27% |
| Mar 31, 2025 | -142.14% |
| Dec 31, 2024 | -88.95% |
| Sep 30, 2024 | -211.18% |
| Jun 30, 2024 | -423.40% |
| Mar 31, 2024 | -609.60% |
| Dec 31, 2023 | -451.50% |
| Sep 30, 2023 | -1,086.41% |
| Jun 30, 2023 | -1,161.53% |
| Mar 31, 2023 | -3,076.86% |
| Dec 31, 2022 | -513.04% |
| Sep 30, 2022 | -2,757.00% |
| Jun 30, 2022 | -2,794.49% |
| Mar 31, 2022 | -3,945.05% |
| Dec 31, 2021 | -3,240.36% |
| Sep 30, 2021 | -33.45% |
| Jun 30, 2021 | -2.47% |